BRCA1 and breast carcinoma: In this study, the ability of RAPTA-T and olaparib in combination and as single agents to inhibit triple-negative BRCA1 wild-type MDA-MB-231 and MDA-MB-468 cells compared with sporadic BRCA1 wild-type MCF-7 breast cancer cells was investigated.